Voyager Therapeutics, Inc. Total Assets

• Voyager Therapeutics, Inc. showed a decrease of -35.8% in Total Assets from 2024 to 2025.
• This data is from Voyager Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
• XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q3 2015: $166.44 million | Q1 2016: $219.98 million | Q2 2016: $209.82 million | Q3 2016: $201.98 million | Q1 2017: $175.09 million | Q2 2017: $158.41 million | Q3 2017: $140.92 million | Q1 2018: $235.03 million | Q2 2018: $214.66 million | Q3 2018: $197.06 million | Q1 2019: $411.35 million | Q2 2019: $388.59 million | Q3 2019: $376.22 million | Q1 2020: $322.61 million | Q2 2020: $297.46 million | Q3 2020: $269.76 million | Q1 2021: $237.72 million | Q2 2021: $208.73 million | Q3 2021: $184.77 million | Q1 2022: $224.18 million | Q2 2022: $188.61 million | Q3 2022: $182.48 million | Q1 2023: $336.29 million | Q2 2023: $315.54 million | Q3 2023: $294.65 million | Q1 2024: $469.59 million | Q2 2024: $436.23 million | Q3 2024: $426.04 million | Q1 2025: $353.24 million | Q2 2025: $322.10 million | Q3 2025: $288.31 million.
• Over the full 12 years of available data (2014 to 2025), Voyager Therapeutics, Inc.'s Total Assets has grown by 2,094.3%.
• Historical annual values: Fiscal year 2025: $252.28 million | Fiscal year 2024: $393.05 million | Fiscal year 2023: $351.28 million | Fiscal year 2022: $159.36 million | Fiscal year 2021: $193.86 million | Fiscal year 2020: $261.58 million | Fiscal year 2019: $354.76 million | Fiscal year 2018: $177.03 million | Fiscal year 2017: $184.48 million | Fiscal year 2016: $189.57 million | Fiscal year 2015: $229.46 million | Fiscal year 2014: $11.50 million.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026